Literature DB >> 30894426

Integrin β1 Promotes the Interaction of Murine IgG3 with Effector Cells.

Carolyn Saylor Hawk1, Carolina Coelho2, Diane Sthefany Lima de Oliveira3, Verenice Paredes4,5, Patrícia Albuquerque6, Anamélia Lorenzetti Bocca3, Ananésia Correa Dos Santos5, Victoria Rusakova7, Heather Holemon7, Ildinete Silva-Pereira3, Maria Sueli Soares Felipe8, Hideo Yagita9, André Moraes Nicola10, Arturo Casadevall11.   

Abstract

Abs exert several of their effector functions by binding to cell surface receptors. For murine IgG3 (mIgG3), the identity of its receptors (and the very existence of a receptor) is still under debate, as not all mIgG3 functions can be explained by interaction with FcγRI. This implies the existence of an alternate receptor, whose identity we sought to pinpoint. We found that blockage of integrin β1 selectively hampered binding of mIgG3 to macrophages and mIgG3-mediated phagocytosis. Manganese, an integrin activator, increased mIgG3 binding to macrophages. Blockage of FcγRI or Itgb1 inhibited binding of different mIgG3 Abs to variable extents. Our results are consistent with the notion that Itgb1 functions as part of an IgG receptor complex. Given the more ancient origin of integrins in comparison with FcγR, this observation could have far-ranging implications for our understanding of the evolution of Ab-mediated immunity as well as in immunity to microorganisms, pathogenesis of autoimmune diseases, and Ab engineering.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30894426      PMCID: PMC6759214          DOI: 10.4049/jimmunol.1701795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors.

Authors:  P Vukovic; P M Hogarth; N Barnes; D C Kaslow; M F Good
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Properties of mouse and human IgG receptors and their contribution to disease models.

Authors:  Pierre Bruhns
Journal:  Blood       Date:  2012-04-25       Impact factor: 22.113

3.  IgG3 is the major source of cryoglobulins in mice.

Authors:  M Abdelmoula; F Spertini; T Shibata; Y Gyotoku; S Luzuy; P H Lambert; S Izui
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

Review 4.  Molecular basis of Fc receptor function.

Authors:  M D Hulett; P M Hogarth
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

5.  The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes.

Authors:  A C Young; P Valadon; A Casadevall; M D Scharff; J C Sacchettini
Journal:  J Mol Biol       Date:  1997-12-12       Impact factor: 5.469

6.  FcgammaRIV: a novel FcR with distinct IgG subclass specificity.

Authors:  Falk Nimmerjahn; Pierre Bruhns; Ken Horiuchi; Jeffrey V Ravetch
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

7.  Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.

Authors:  P W Parren; P A Warmerdam; L C Boeije; P J Capel; J G van de Winkel; L A Aarden
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

8.  Human T cell activation induced by a monoclonal mouse IgG3 anti-CD3 antibody (RIV9) requires binding of the Fc part of the antibody to the monocytic 72-kDa high-affinity Fc receptor (FcRI).

Authors:  J L Ceuppens; F Van Vaeck
Journal:  Cell Immunol       Date:  1989-01       Impact factor: 4.868

9.  A role for complement in feedback enhancement of antibody responses by IgG3.

Authors:  Teresita Díaz de Ståhl; Jörgen Dahlstrom; Michael C Carroll; Birgitta Heyman
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

10.  Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.

Authors:  J Mukherjee; A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  6 in total

1.  Pulling, failing, and adaptive mechanotransduction of macrophage filopodia.

Authors:  Rebecca Michiels; Nicole Gensch; Birgit Erhard; Alexander Rohrbach
Journal:  Biophys J       Date:  2022-08-04       Impact factor: 3.699

Review 2.  Cell-specific expression and function of laminin at the neurovascular unit.

Authors:  Abhijit Nirwane; Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2022-07-07       Impact factor: 6.960

3.  Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.

Authors:  Lynn Bimler; Sydney L Ronzulli; Amber Y Song; Scott K Johnson; Cheryl A Jones; Teha Kim; Duy T Le; S Mark Tompkins; Silke Paust
Journal:  J Virol       Date:  2020-12-02       Impact factor: 6.549

4.  The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Michael P Motley; Elizabeth Diago-Navarro; Kasturi Banerjee; Sean Inzerillo; Bettina C Fries
Journal:  mBio       Date:  2020-09-08       Impact factor: 7.867

5.  Mouse IgG3 binding to macrophage-like cells is prevented by deglycosylation of the antibody or by Accutase treatment of the cells.

Authors:  Alicja Karabasz; Monika Bzowska; Joanna Bereta; Maria Czarnek; Maja Sochalska; Tomasz Klaus
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

6.  Proteome Profiling of PMJ2-R and Primary Peritoneal Macrophages.

Authors:  Alexander L Rusanov; Peter M Kozhin; Olga V Tikhonova; Victor G Zgoda; Dmitry S Loginov; Adéla Chlastáková; Martin Selinger; Jan Sterba; Libor Grubhoffer; Nataliya G Luzgina
Journal:  Int J Mol Sci       Date:  2021-06-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.